ArticleBMC women's health2026
Preliminary clinical observation on the treatment of adenomyosis by partial embolization of uterine artery with novel material combination: a case series.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aims to investigate the efficacy of novel embolic materials in the treatment of adenomyosis via partial embolization of uterine arteries.
methodsFrom June 2023 to June 2025, we used gelatin sponge particles, liquid sclerosant, and temperature-sensitive liquid embolic agent to perform partial embolization of uterine arteries on 6 patients with adenomyosis who had failed to respond to other treatments. The Visual Analogue Scale (VAS) was used to assess the degree of postoperative abdominal pain during hospitalization and the improvement of post-operative dysmenorrhea. To evaluate the recovery of menstrual function, data on changes in the number of sanitary pads/period pants used during menstruation and changes in the duration of menstrual periods were collected via questionnaires before and after UAE, while changes in hemoglobin levels and red blood cell counts were assessed through complete blood counts. Additionally, changes in uterine volume, maximal junctional zone thickness (JZmax), and minimal junctional zone thickness (JZmin) were assessed via magnetic resonance imaging (MRI). The Uterine Fibroid Symptom and Quality of Life (UFS-QOL) scale was employed to evaluate the patients’ symptoms and quality of life both pre-operatively and post-operatively.
resultsIn patients with adenomyosis, UAE using gelatin sponge particles, liquid sclerosing agent, and temperature-sensitive liquid embolic agent can achieve favorable therapeutic effects. All patients showed significant improvement in their clinical symptoms, including reduced dysmenorrhea, shortened menstrual periods, and decreased menstrual flow (as evidenced by a marked reduction in the use of sanitary pads/period pants during menstruation). The junctional zone differential (JZdiff), JZmax, and uterine volume of all patients decreased. The UFS-QOL scores also indicated that patients’ symptoms had been significantly alleviated and their quality of life had substantially improved.
conclusionOur research results emphasize the importance of embolic materials in UAE. Ideal embolic materials should be able to precisely embolize the feeding arteries of adenomyotic lesions and achieve good therapeutic effects without the need to embolize the main trunks or large branches of the uterine arteries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.